Ignite Creation Date:
2025-12-24 @ 12:55 PM
Ignite Modification Date:
2026-02-26 @ 12:21 AM
Study NCT ID:
NCT05131061
Status:
COMPLETED
Last Update Posted:
2022-07-15
First Post:
2021-11-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism
Sponsor:
Qifu Li
Organization:
Study Overview
Official Title:
68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism subtype
Detailed Description:
This is a prospective study. We will enroll 100 patients with definite diagnosis of PA using adrenal venous sampling(AVS) as the gold standard for subtype to evaluate the value of 68Ga-pentixaforPET/CT in the diagnosis of PA.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: